Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S005 - Cutaneous Lymphomas

Friday, February 16; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate, work-up, diagnose and design a treatment course for patients with different forms of cutaneous lymphomas (including B- and T-cell types)
  • Analyze a descriptively written pathology report regarding a diagnosis of cutaneous lymphoma and design a treatment plan for such a patient
  • Recognize molecular advances in cutaneous lymphomas

Description

This session will provide an in-depth and comprehensive review of the classic clinical and histopathologic presentations of different forms of cutaneous T-cell and B-cell lymphoma. In addition, management of both early and advanced stage cutaneous lymphoma will be reviewed. How to interpret a pathology report that is descriptively written (i.e. a specific diagnosis is not given) and then how to treat such a patient will be discussed as well. The session will also cover molecular advances in cutaneous lymphoma.

Disclosures

  • Ai, Weiyun, MD, PhD: no financial relationships exist with commercial interests.
  • Charli-Joseph, Yann, MD: no financial relationships exist with commercial interests.
  • Choi, Jaehyuk, MD, PhD: no financial relationships exist with commercial interests.
  • Guitart, Joan, MD: Actelion – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – A(Fees); Soligenix, Inc – I(Grants/Research Funding); Tetralogic Pharmaceuticals – I(Grants/Research Funding);
  • Kim, Youn H., MD: Eisai Pharmaceuticals – A(H), I(Grants/Research Funding); Forty Seven Inc. – I(Grants/Research Funding); Horizon Pharma, Inc. – I(Grants/Research Funding); Innate Pharma, S.A. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), I(OB); Merck & Co., Inc. – I(Grants/Research Funding); Millennium Pharmaceuticals – A(H), I(OB); miRagen Therapeutics, Inc. – I(Grants/Research Funding); Neumedicine, Inc. – I(Grants/Research Funding); Portola Pharmaceuticals, Inc. – I(Grants/Research Funding); Seattle Genetics – C(H); Soligenix, Inc – I(Grants/Research Funding);
  • McCalmont, Timothy H., MD: no financial relationships exist with commercial interests.
  • Pincus, Laura, MD: no financial relationships exist with commercial interests.
  • Spicknall, Kerith E., MD: no financial relationships exist with commercial interests.
Schedule
Friday, February 16
9:00 AM
Dr. Pincus / Introduction and Mycosis fungoides, mycosis fungoides variants and Sezary syndrome
9:25 AM
Charli-Joseph / Other forms of cutaneous T-cell lymphoma
9:45 AM
Dr. Spicknall / B-cell lymphoma
10:00 AM
Dr. Guitart / Management of early stage disease
10:20 AM
Ai / Management of late stage disease
10:40 AM
Dr. McCalmont / How to interpret a descriptive pathology report of cutaneous lymphoma
11:00 AM
Dr. Kim / How I treat patients whose biopsies are reported descriptively
11:20 AM
Dr. Choi / Molecular advances in cutaneous lymphoma
11:45 AM
All faculty / Questions/Answers
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 6C
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Laura Pincus, MD, FAAD
Speakers
  • Jaehyuk Choi, MD, PhD, FAAD
  • Joan Guitart, MD, FAAD - Handout
  • Kerith E. Spicknall, MD, FAAD - Handout
  • Timothy H. McCalmont, MD - Handout
  • Weiyun Ai, MD, PhD
  • Yann Charli-Joseph, MD
  • Youn H. Kim, MD, FAAD - Handout